Three ‐year safety, efficacy and persistence data following the daily use of mirabegron for overactive bladder in the clinical setting: A Japanese post‐marketing surveillance study

LUTS: Lower Urinary Tract Symptoms, EarlyView.

Source: LUTS: Lower Urinary Tract Symptoms - August 6, 2018 Category: Urology & Nephrology Authors: Daisuke Kato , Hiromi Tabuchi , Satoshi Uno Source Type: research